Plain-English translation of NCT06161974 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called olutasidenib combined with temozolomide (a standard chemotherapy drug) as a maintenance treatment for young patients newly diagnosed with high-grade gliomas—aggressive brain tumors—that have a specific IDH1 genetic mutation. After you complete radiation therapy, you would receive the medication combined with chemotherapy for several months, followed by the medication alone. The trial aims to find the right dose and see whether this combination can help patients live longer without their cancer progressing.
High-grade brain gliomas are very serious cancers, especially in children and young adults, and current treatments do not work well enough for many patients. Researchers discovered that some of these tumors have a specific genetic change (IDH1 mutation) that this new treatment may be able to target, potentially offering better outcomes than standard treatment alone.
You likely qualify if…
You likely don't qualify if…
After completing your radiation therapy, you would take olutasidenib (a pill or tablet) combined with temozolomide chemotherapy for 13 cycles (typically about 13 months). After that, you would continue taking olutasidenib alone for another 13 cycles. You would have regular visits to the research center for blood tests, scans to check how your tumor is responding, and to monitor for any side effects. The study will track how long you stay without your cancer getting worse and assess how well the treatment works for you.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States